Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.
Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS. Miller DH, et al. Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar. Ann Clin Transl Neurol. 2018. PMID: 29560379 Free PMC article.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A. Munger KL, et al. Among authors: miller dh. Neurology. 2015 Nov 10;85(19):1694-701. doi: 10.1212/WNL.0000000000002099. Epub 2015 Oct 9. Neurology. 2015. PMID: 26453645 Free PMC article. Clinical Trial.
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators. Lublin F, et al. Among authors: miller dh. Lancet. 2016 Mar 12;387(10023):1075-1084. doi: 10.1016/S0140-6736(15)01314-8. Epub 2016 Jan 28. Lancet. 2016. PMID: 26827074 Free article. Clinical Trial.
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.
Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, De Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, Montalban X; MAGNIMS study group. Rovira À, et al. Nat Rev Neurol. 2015 Aug;11(8):471-82. doi: 10.1038/nrneurol.2015.106. Epub 2015 Jul 7. Nat Rev Neurol. 2015. PMID: 26149978 Review.
Lack of association between antimyelin antibodies and progression to multiple sclerosis.
Kuhle J, Pohl C, Mehling M, Edan G, Freedman MS, Hartung HP, Polman CH, Miller DH, Montalban X, Barkhof F, Bauer L, Dahms S, Lindberg R, Kappos L, Sandbrink R. Kuhle J, et al. Among authors: miller dh. N Engl J Med. 2007 Jan 25;356(4):371-8. doi: 10.1056/NEJMoa063602. N Engl J Med. 2007. PMID: 17251533 Free article. Clinical Trial.
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Rudick RA, et al. Among authors: miller dh, miller d. Ann Neurol. 2007 Oct;62(4):335-46. doi: 10.1002/ana.21163. Ann Neurol. 2007. PMID: 17696126 Clinical Trial.
1,171 results